Drugs / recombinant human GH
recombinant human GH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01066052 | Feb 1992 → Mar 1999 | Turner syndrome | Merck KGaA, Darmstadt, Germany | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human GH | “Earlier diagnosis enables earlier therapeutic intervention, such as with recombinant human GH (r-hGH), which may help to prevent growth retardation.” PMID 21398400 ↗ Mar 2011 |
| Known as | r-hGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01066052 ↗ |
| Known as | recombinant human growth hormone | “The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years.” NCT01066052 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human growth hormone (r-hGH) treatment” NCT01066052 ↗ |
| Route | Subcutaneous | “Subcutaneous administration.” NCT01066052 ↗ |